M. Andrew Holtman Ph.D.

Partner

Andrew Holtman practices primarily patent litigation and prosecution in the biotechnology, medical device, pharmaceutical, and mechanical areas. He has considerable experience with due diligence investigations, particularly in the pharmaceutical and diagnostics field. His practice also includes client counseling and opinion work.

The subject matter of Dr. Holtman's work covers most biotechnology-related fields, including plant molecular biology, genetics, biochemistry and immunology, as well as pharmaceuticals, medical devices, and other bio-mechanical technologies. He has significant experience coordinating multi-jurisdictional patent practice between the United States, the European Patent Office (EPO), and numerous European court systems. He oversees litigations in France, Germany, Ireland, and the United Kingdom, as well as oppositions at the EPO.

Dr. Holtman has managed teams of attorneys performing comprehensive freedom-to-operate, validity/enforceability, and ownership investigations. In addition, he teaches advanced courses on due diligence, and has lectured on litigation practice with an emphasis on changing Federal Circuit law.

While earning his law degree, Dr. Holtman joined Finnegan as a year-round summer associate and law clerk. Before entering the practice of law, he served as a research fellow in the plant biology graduate program at Rutgers University. His work focused on the identification and molecular characterization of genetic operons associated with fungal parasitism. Dr. Holtman also served as a research associate for an immunology corporation studying coat-protein and cellular interactions of HIV, and corresponding screening assays.

Highlights

• Bear Creek Technologies, Inc. v. Verizon Services Corp. (E.D. Va.). Represents Verizon and others in a patent suit relating to Voice over Internet Protocol (VoIP) technology.
• Rolls-Royce, PLC. v. United Technologies Corp. (E.D. Va.). Represented UTC in a defensive patent suit related to swept fan blades for ducted gas turbine engines used on contemporary commercial and private aircraft.
• Certain Turbomachinery Blades, Engines and Components Thereof, 337-TA-751 (ITC). Represented UTC in a offensive patent suit related to swept fan blades for ducted gas turbine engines.
• Eli Lilly and Company v. Actavis Elizabeth LLC (D.N.J.). Represented Eli Lilly and Company in an ANDA action related to the Lilly's Strattera^® product, atomoxetine hydrochloride, which is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 and older, teens, and adults.
• Represented Orion Corporation in multiple ANDA actions in D.N.J. and D. Del. related to Orion's Stalevo^® and Comtan^® products approved for the treatment of Parkinson’s disease.

Professional Activities

• District of Columbia Bar, Intellectual Property Section (chair, Trade Secret Committee, 2008-present)
• American Bar Association
• American Chemical Society
• American Intellectual Property Law Association
• Federal Circuit Bar Association

Select Publications

• Coauthor. "Freedom to Operate Analysis Could Be Key to Crowdfunding Success," BNA's Patent, Trademark & Copyright Journal, May 31, 2013.
• Coauthor. "Claims to Antibodies Not Adequately Described by Disclosing Known Antigens to Which They Bind," Journal of Intellectual Property Law & Practice, 2011.
• Coauthor. "The Current and Future Status of False Marking Cases," Bloomberg Law Reports, Aug. 22, 2011.
• Coauthor. "The Expansion and Possible Contraction of False Marking Cases," The Federal Circuit Bar Association Bench & Bar Newsletter, June 2011.
• Coauthor. "Stemming the Tide of False Marking Cases," Bloomberg Law Reports, May 16, 2011.